The effectiveness of topiramate in comparison with acetazolamide in ?children

Evaluation of the effectiveness of topiramate in comparison with acetazolamide in ?children with external hydrocephalus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201105049278N1

Enrollment

Registered

2021-02-01

Start date

2020-09-22

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

External hydrocephalus. Hydrocephalus, unspecified

Interventions

Intervention 1: Intervention group: Intervention group: Acetazolamide from Iran Daroo Company (receiving 20 mg per kg of infant weight daily in two divided doses for 2 months). Intervention 2: Interve

Eligibility

Sex/Gender

All

Age

3 Months to 9 Months

Inclusion criteria

Inclusion criteria: Being between 3 and 9 months old Final diagnosis of external hydrocephalus based on clinical evidence and brain imaging Normal status of cognitive motor development (based on interview and clinical examination)

Exclusion criteria

Exclusion criteria: Having a brain tumor and subdural hematoma Symptoms of increased intracranial pressure Abnormal cognitive motor development Existence of internal hydrocephalus

Design outcomes

Primary

Measure	Time frame
External hydrocephalus. Timepoint: At the end of each month, the head circumference is measured and at the end of the 2-month treatment period, patients undergo Brain Sonography, and one month after the end of the 2-month drug intervention, patients are evaluated for external hydrocephalus. Method of measurement: Brain Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHosein Mahmoudzadeh

Kashan University of Medical Sciences

mahmoudzadeh-h@mail.kaums.ac.ir+98 31 5550 0111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026